<code id='1F6933BEA1'></code><style id='1F6933BEA1'></style>
    • <acronym id='1F6933BEA1'></acronym>
      <center id='1F6933BEA1'><center id='1F6933BEA1'><tfoot id='1F6933BEA1'></tfoot></center><abbr id='1F6933BEA1'><dir id='1F6933BEA1'><tfoot id='1F6933BEA1'></tfoot><noframes id='1F6933BEA1'>

    • <optgroup id='1F6933BEA1'><strike id='1F6933BEA1'><sup id='1F6933BEA1'></sup></strike><code id='1F6933BEA1'></code></optgroup>
        1. <b id='1F6933BEA1'><label id='1F6933BEA1'><select id='1F6933BEA1'><dt id='1F6933BEA1'><span id='1F6933BEA1'></span></dt></select></label></b><u id='1F6933BEA1'></u>
          <i id='1F6933BEA1'><strike id='1F6933BEA1'><tt id='1F6933BEA1'><pre id='1F6933BEA1'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:fashion    Page View:5
          A scientist working at SQZ Biotechnologies in Watertown's Arsenal Yards. -- biotech coverage from STAT
          A scientist working at SQZ Biotechnologies in Watertown, Mass. David L Ryan/Globe Staff

          Next stop: Beacon Hill.

          Governor Maura Healey’s long-awaited plan to double down on state funding for the biotech and medical technology sector came into focus Thursday with the announcement she’ll seek $1 billion over the next decade to reauthorize the state’s 16-year-old life sciences initiative.

          advertisement

          But lawmakers so far are noncommittal on funding the plan. The proposal — dubbed “Life Sciences 3.0″ — is part of a larger economic development bill the Healey administration is expected to file soon. Several expressed support for an industry in which Massachusetts is a leader, but also noted the spending request comes at a time of competing priorities.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          The high cost of giving birth even with insurance
          The high cost of giving birth even with insurance

          AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

          read more
          Making the case for fair compensation in clinical trials
          Making the case for fair compensation in clinical trials

          AdobeI’vebeenonthreesidesofthehealthcareequation:I’vebeatenstage4colorectalcancer,I’mthemotherofason

          read more
          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more

          Biogen joins immunology wave with $1.15 billion acquisition of HI

          RubyWallauforSTATBiogenisjoiningtheindustry’sfervoroverimmuneandinflammatorydiseasedrugdevelopmentwi